Nikhil Prasad Fact checked by:Thailand Medical News Team Sep 22, 2025 18 hours, 21 minutes ago
Medical News: Major Breakthrough in Managing Menopause Symptoms
An international clinical trial has revealed highly promising results for elinzanetant, a new non-hormonal drug designed to treat vasomotor symptoms of menopause, including hot flashes and night sweats. These symptoms affect millions of women worldwide, often disrupting sleep, mood, and overall quality of life. Traditional hormone replacement therapy has long been used, but safety concerns and unwanted side effects have left many searching for alternatives.
New Menopause Drug Cuts Hot Flashes by Over 70 Percent
This
Medical News report covers the large-scale OASIS-3 trial, which enrolled more than 600 postmenopausal women between the ages of 40 and 65 across 83 medical centers in North America and Europe. Participants were randomly assigned to receive either 120 milligrams of elinzanetant daily or a placebo for an entire year.
Results Show Sustained Improvements
By week 12 of treatment, women taking elinzanetant saw a 73 percent reduction in both the frequency and severity of hot flashes and night sweats compared with the placebo group. These improvements were not fleeting; instead, they were sustained for the full 52 weeks of the trial. Researchers also found that women receiving the drug reported fewer sleep disturbances and improvements in overall quality of life, although the trial was not specifically designed to statistically confirm all secondary outcomes.
Safe Alternative to Hormone Therapy
One of the most encouraging findings was the drug’s safety profile. Over the course of the study, elinzanetant showed no negative effects on liver function or bone density—two areas of concern with long-term treatments. Reported side effects were generally mild and included fatigue, sleepiness, and headaches. Importantly, researchers also monitored breast health and endometrial thickness and found no significant issues.
This makes elinzanetant particularly promising for women who cannot or choose not to take hormone therapy, which while effective, is linked to an increased risk of breast cancer, cardiovascular disease, and stroke in some populations.
How Elinzanetant Works
Elinzanetant is not a hormone. Instead, it is a dual neurokinin-1 and neurokinin-3 receptor antagonist. These receptors are part of the brain’s thermoregulatory system and play a role in triggering hot flashes. By blocking them, elinzanetant helps restore balance without altering hormone levels. This mechanism represents a new class of treatment for menopause symptoms, offering a long-awaited alternative pathway to relief.
Broader Implications and Regulatory Status
Previous smaller studies, including the OASIS-1 and OASIS-2 trials, had hinted at elinzanetant’s potential, but the OASIS-3 trial provides robust, long-term data confirming both effectiveness and safety across a diverse population of women. Researchers believe the drug could
also benefit women undergoing endocrine therapy for breast cancer, who often experience severe hot flashes but are unable to use hormone replacement therapy.
Despite the compelling results, the drug is not yet approved for public use. The U.S. Food and Drug Administration (FDA) was expected to make a decision earlier in 2025 but delayed its ruling in July, requesting additional review of the trial data. Approval would position elinzanetant as a groundbreaking new option in menopause care.
Conclusion
The OASIS-3 trial demonstrates that elinzanetant has the potential to transform menopause treatment by offering a non-hormonal, safe, and highly effective option for women struggling with vasomotor symptoms. Its ability to cut hot flashes and night sweats by more than 70 percent while improving sleep and quality of life—and without serious side effects—marks a turning point in women’s health. If regulatory bodies move forward with approval, elinzanetant could soon become the standard of care for millions worldwide, especially those unable to use hormone therapy.
The study findings were published in the peer reviewed journal: JAMA Internal Medicine
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2838538
For the latest on menopause, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/menopause-news-american-study-finds-that-low-fat-vegan-diet-with-soy-decreases-hot-flashes-by-95-percent
https://www.thailandmedical.news/news/fezolinetant,-new-drug-for-hot-flash-treatment-for-women-with-menopause
https://www.thailandmedical.news/articles/menopause
Share
Tweet
Share
